Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Castration Resistance Accelerates Prostate Cancer Kinetics.

The Prostate·2026
Same author

The molecular pathology of prostate cancer: an update for practising pathologists.

Histopathology·2026
Same author

Subclonal Complete Loss of <i>CDKN1B</i> as a Common Genomic Alteration in Prostate Cancer: Associations with Race and Prostate Cancer Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: May 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MYC and Prostate Cancer.

Cheryl M Koh1, Charles J Bieberich, Chi V Dang

  • 1Departments of Pathology.

Genes & Cancer
|July 23, 2011
PubMed
Summary
This summary is machine-generated.

Prostate cancer initiation involves MYC activation, driving an embryonic stem cell-like signature and repressing differentiation. This finding offers new therapeutic strategies targeting MYC in early-stage prostate cancer.

Keywords:
prostate cancerprostatic intraepithelial neoplasiatumor initiating cells

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Experiment Videos

Last Updated: May 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer, primarily adenocarcinoma, is a common malignancy in elderly men, with variable progression from indolent to aggressive forms.
  • Somatic genetic and epigenetic alterations, including PTEN/p53 loss and ETS gene fusions, are implicated in prostate cancer progression and invasion.
  • MYC alterations in chromosome 8q24 have been linked to aggressiveness, with recent evidence suggesting early activation in precursor lesions.

Purpose of the Study:

  • To investigate the role of MYC in the initiation and early progression of prostate cancer.
  • To elucidate the molecular mechanisms by which MYC influences prostate cancer development.
  • To explore potential therapeutic avenues based on MYC's role in prostate cancer.

Main Methods:

  • Analysis of human prostate tissues, including precursor lesions like prostatic intraepithelial neoplasia.
  • Utilisation of genetically engineered mouse models to recapitulate prostate cancer initiation and progression.
  • Integration of data from human tissues and mouse models to build a comprehensive molecular picture.

Main Results:

  • MYC is activated at the earliest stages of prostate cancer, including in tumor-initiating cells within prostatic intraepithelial neoplasia.
  • MYC activation drives an embryonic stem cell-like gene expression signature, characterized by increased ribosome biogenesis.
  • MYC also plays a role in repressing cellular differentiation, contributing to early disease progression.

Conclusions:

  • MYC is a critical factor in prostate cancer initiation and early progression, not just aggressiveness.
  • The MYC-driven signature suggests a reprogramming of prostate cells towards a stem-like state.
  • Understanding MYC's role opens potential for novel therapeutic strategies targeting this pathway in prostate cancer.